Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Axovant Sciences Ltd. (SIOX : NSDQ)
 
 • Company Description   
Axovant Sciences Ltd. is a biopharmaceutical company which focuses on the acquisition, development and commercialization of therapeutics for the treatment of neurodegenerative disorders. Its product candidate includes RVT-101 which is in different clinical trial for the treatment of Alzheimer's disease and other forms of dementia. Axovant Sciences Ltd. is based in Hamilton, Bermuda.

Number of Employees: 42

 
 • Price / Volume Information   
Yesterday's Closing Price: $ Daily Weekly Monthly
20 Day Moving Average: shares
Shares Outstanding: 72.94 (millions)
Market Capitalization: $ (millions)
Beta:
52 Week High: $2.95
52 Week Low: $0.23
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week % %
12 Week % %
Year To Date % %
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
130 WEST 42ND STREET 26TH FLOOR
-
NEW YORK,NY 10036
USA
ph: 877-746-4891
fax: -
investors@siogtx.com http://www.siogtx.com
 
 • General Corporate Information   
Officers
Pavan Cheruvu - Chief Executive Officer and Director
Frank Torti - Chairperson
David Nassif - Chief Financial Officer and Chief Accounting Offic
Berndt Modig - Director
Senthil Sundaram - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: G0750W203
SIC: 2834
Fiscal Year
Fiscal Year End: March
Last Reported Quarter: 12/01/21
Next Expected EPS Date: 06/08/22
Share - Related Items
Shares Outstanding: 72.94
Most Recent Split Date: 5.00 (0.13:1)
Beta:
Market Capitalization: $ (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: %
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-1.18 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 06/08/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: -
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -75.00%
vs. Previous Quarter: -20.69%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -
12/31/21 - -68.88
09/30/21 - -52.75
ROA
03/31/22 - -
12/31/21 - -61.63
09/30/21 - -48.07
Current Ratio
03/31/22 - -
12/31/21 - 5.95
09/30/21 - 10.57
Quick Ratio
03/31/22 - -
12/31/21 - 5.95
09/30/21 - 10.57
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Book Value
03/31/22 - -
12/31/21 - 1.05
09/30/21 - 1.36
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - -
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - -
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©